Glass Lewis Endorses Aptose Biosciences’ Plan of Arrangement with Hanmi Pharmaceutical: What Investors Need to Know

Key Highlights from the Aptose Biosciences Form 8-K Filing

• Glass Lewis, a leading independent proxy advisory firm, has recommended that shareholders vote in favor of Aptose Biosciences Inc.’s (TSX: APS; OTC: APTOF) proposed Plan of Arrangement with Hanmi Pharmaceutical.
• The Plan of Arrangement will be voted on at an upcoming special meeting of shareholders.
• Aptose issued a press release on March 23, 2026, emphasizing the recommendation and reminding shareholders about the voting deadline.

Details of the Glass Lewis Recommendation

Glass Lewis evaluated the proposed transaction and has publicly endorsed the “FOR” vote for the special resolution regarding the Arrangement. This is a significant development, as Glass Lewis is widely respected for its independent analysis and influence among institutional investors. Their support often sways the outcome of important shareholder votes.

What is the Proposed Arrangement?

The arrangement is between Aptose Biosciences and Hanmi Pharmaceutical, a strategic development that could materially affect the company’s future operations, funding, and potentially its market value. The press release does not provide specific financial terms or deal structure in the excerpt, but the nature of a “Plan of Arrangement” typically involves a merger, acquisition, or significant strategic partnership that could result in new capital, changes in management, or an altered competitive landscape for Aptose.

Price-Sensitive and Shareholder-Impacting Elements

• Institutional Support: The Glass Lewis recommendation is likely to influence a large number of institutional and retail investors, increasing the probability of the Arrangement being approved.
• Potential Change of Control or Strategic Direction: Approval of the Arrangement could result in substantial changes to Aptose’s business, competitive positioning, or shareholder structure.
• Voting Deadline Reminder: The company issued a reminder about the voting deadline for the upcoming special meeting. Shareholders who do not vote could miss their chance to shape the transaction outcome.

Forward-Looking Statements and Risks

The company’s press release contains standard forward-looking statements, cautioning that actual results may differ materially from those anticipated. Risks include:

• The possibility that the Arrangement may not be completed as planned.
• Regulatory or legal obstacles that could delay or block the transaction.
• Disruptions to Aptose’s business, including loss of personnel or focus due to deal uncertainty.
• Industry or market changes that could affect the deal’s rationale or value.

Shareholders are urged not to place undue reliance on forward-looking statements and to consider all risks disclosed by the company in its public filings.

Other Noteworthy Information

• No Securities Registered on U.S. Exchanges: The filing indicates that there are no Aptose securities currently registered under Section 12(b) of the Exchange Act, and no trading symbols are listed for U.S. markets.
• Emerging Growth Company Status: Aptose is not classified as an emerging growth company.
• Exhibits: The press release (Exhibit 99.1) and the cover page interactive data file (Exhibit 104) are filed with the SEC, providing additional information for investors.

Investor Takeaways

The Glass Lewis endorsement of the Plan of Arrangement is a critical development for Aptose Biosciences and its shareholders. Approval of the transaction could bring significant changes to the company’s strategic direction, financial profile, and market value. Investors should carefully review all materials, consider the risks, and participate in the shareholder vote to ensure their interests are represented.

Disclaimer

This article is for informational purposes only and does not constitute investment advice, an offer to buy or sell securities, or a solicitation of any vote or approval. Investors should consult official company filings, press releases, and their own financial advisors before making investment decisions. Past performance and third-party recommendations are not indicative of future results. Actual outcomes may differ materially from any forward-looking statements.